Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ad-p53 + Checkpoint Inhibitors in Recurrent/Metastatic Cancers
NCT03544723Phase 2Unknown
- Sponsor
- MultiVir, Inc.
- Start
- Oct 2018
- Primary completion
- Jun 2022
- Modality
- Gene Editing, Gene Silencing, Viral Vectors
- Countries
- 1
01
Overview
A Phase 2 trial of Ad5CMV-p53 in head and neck squamous cell carcinoma (HNSCC), solid tumor, lymphoma, sponsored by MultiVir, Inc.. Status: unknown.
02
Drugs
Ad5CMV-p53
03
Conditions
head and neck squamous cell carcinoma (HNSCC)solid tumorlymphoma
Beyond the preview
Go deeper on NCT03544723.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03544723.